The Trump administration said it will restart the risk adjustment payment program just weeks after suspending the payments; the first pill in a decade has been approved to treat pain caused by endometriosis; Eli Lilly executives said during the second quarter earnings call that the idea of importing drugs from abroad was “the wrong road to go down.”
The Trump administration said it will restart the risk adjustment payment program established under the Affordable Care Act that pays money to insurers who take on higher-risk patients. According to The New York Times, in reversing the decision, the administration is acknowledging that ending the payments could destabilize the insurance markets. The program was suspended July 8 after a court ruling. CMS’ decision had put $10.4 billion in risk adjustment transfer payments for the 2017 benefit year on hold. Payments will resume around October 22.
The first pill in a decade has been approved to treat pain caused by endometriosis, a common gynecologic disorder that affects approximately 1 in 10 women of reproductive age. It can cause severe pain and infertility. Testing of the drug found that it significantly reduced menstrual pain in 45% of women on the low dose and in 75% of women on the high dose, reported the AP. Side effects include hot flashes, headaches, and bone thinning. The drug will cost $845 every 4 weeks without insurance.
During Eli Lilly’s second quarter earnings call, executives said the idea of importing drugs from abroad was “the wrong road to go down.” The Hill reported that Lilly’s CEO said regulatory reforms would more successfully improve access to prescription drugs and keep prices affordable. He added that he is open to changing the Medicare drug rebate structure, under which drug companies negotiate rebates with insurers or pharmacy benefit managers.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Chakra Chaulagain: PFS Is the "Bare Minimum," but OS Is Ideal for Choosing Between MM Therapies
March 28th 2024Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Alopecia Areata Impacts Patient Perception, Quality of Life
March 27th 2024Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.
Read More